Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

Neuro-Oncology

Volumn 12, Issue 6, 2010, Pages 603-607

  Scott, Brian J ^a,b   Quant, Eudocia C ^a,b   McNamara, Margaret B ^b   Ryg, Peter A ^a   Batchelor, Tracy T ^a   Wen, Patrick Y ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bevacizumab; Recurrent glioblastoma; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; ERLOTINIB; IRINOTECAN; LAPATINIB; LOMUSTINE; MONOCLONAL ANTIBODY; PAZOPANIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BONE MARROW TOXICITY; BONE NECROSIS; BRAIN CANCER; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LUNG EMBOLISM; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SALVAGE THERAPY; YOUNG ADULT;

EID: 77952523530     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop073     Document Type: Article

References (23)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. World Health Organization Classification of Tumors of the Central Nervous System. Lyon, France: IARC Press; 2007.
2. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 2001;19(19):3997-3999.
3. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent highgrade gliomas. Neuro-Oncology. 2008;10(2):162-170.
4. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049.
5. Chi A, Norden AD, Wen PW. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther. 2007;7(11):1537-1560.
6. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer. 2008;8:579-591.
7. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(suppl 3):11-16.
8. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-Oncology. 2008;10(6):940-945.
9. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, et al. SU6668 inhibits Flk-1/KDR and PDGRFb in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 2002;16:681-690.
10. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012-2021.
11. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Clin Cancer Res. 2007;25(30):4722-4729. (Pubitemid 350086473)
12. Cloughsey TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). ASCO 2008 Annual Meeting Oral Presentation, abstract 2010b, Chicago, IL.
13. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
14. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95.
15. Batchelor TT, Sorensen AG, Ancukiewicz M, Duda DG, Louis DN, Plotkin SR, et al. A phase II trial of AZD 2171 (cediranib), and oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(suppl 18S):abstract 2001.
16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
17. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
18. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
19. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
20. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, et al. A phase II trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American brain tumor consortium study. Neuro-Oncology. 2006;8(2):189-193. (Pubitemid 46542664)
21. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
22. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñ als F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.
23. Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, et al. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro-Oncology. 2009;11(1):92-95.